ClinicalTrials.gg
RecruitingNCT06871969CROSSROADS-EEGUpdated Oct 3, 2025

Clinical Evaluation of EEG Device for the Triage of Stroke Patients in the Ambulance

An interventional study of Dry electrode EEG in Ischemic Stroke, Stroke and Cardiovascular Diseases, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
275
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Ischemic Stroke with a site in Netherlands — 14 open to participants now, 17 under way, 2 of them phase 3. Ischemic Stroke · Netherlands.

Planned enrollment
20th of 34
275 · median 447
Started
2025
with 1 other
No phase
13 of 45
6 open now
Primary completion
2026-12
later than 8 of 16 live
Registered
40th of 45
by date
Lead sponsor
7 of 45
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 45 studies in Ischemic Stroke with a site in Netherlands, this one is the 20th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 40th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

14 of the 45 studies in Ischemic Stroke with a site in Netherlands are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Ischemic Stroke with a site in Netherlands, or all of them as a file.
02

Study summary

Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) strokes, but it can only be performed in specialized hospitals. Since ambulance personnel cannot determine if a patient is eligible for EVT, 54% of LVO stroke patients are initially taken to non-EVT-capable hospitals, resulting in an average delay of 1 hour in time-to-EVT in the Netherlands. To reduce this delay, it is crucial for ambulance personnel to identify potential LVO stroke patients and directly transport them to EVT-capable hospitals. Dry electrode electroencephalography (EEG) has shown high diagnostic accuracy for detecting LVO strokes, but in 32% of patients, the EEG signal quality was too poor to analyze.

To address this issue, TrianecT developed StrokePointer, a portable EEG-based triage device designed to collect and analyze EEG data in patients with suspected acute stroke. The objective of this study is to validate the effectiveness and safety of StrokePointer in detecting LVO stroke among patients with a suspected stroke in the pre-hospital setting.

Read the detailed description

RATIONALE Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) stroke. However, EVT can only be performed in specialized hospitals and its effect on functional outcome rapidly decreases with passing time (time = brain). Since ambulance personnel cannot determine whether a patient has a stroke that is eligible for EVT, 54% of patients with an LVO stroke are primarily presented at a non-EVT capable hospital. These patients then require interhospital transfer, resulting in average delay in time-to-EVT of 1 hour in the Netherlands. Therefore, providing ambulance personnel with tools to identify patients with a possible LVO stroke in the ambulance, allowing direct transport to an EVT capable hospital, is much needed. Dry electrode electroencephalography (EEG) has shown to have a high diagnostic accuracy for LVO stroke detection among patients with a suspected stroke (area under the receiving operating curve [AUC]: 0.91). However, in 32% of patients EEG signal quality was too poor to analyse. A new portable EEG-based triage device (StrokePointer) has been developed by TrianecT with the aim to collect and analyse EEG data in patients suspected of acute stroke. In this study, we intend to validate the safety and effectiveness of the device.

HYPOTHESIS:

  1. StrokePointer device can measure EEG data of sufficient quality in >85% of patients, and has a good diagnostic accuracy (AUC>0.8) for LVO stroke detection in the pre-hospital setting.
  2. Usability of StrokePointer device is rated as "good" on average by ambulance personnel.
  3. StrokePointer is safe to use in an acute care setting.

OBJECTIVE Primary objective is to validate the data quality and diagnostic accuracy of StrokePointer to detect LVO stroke among patients with a suspected stroke in the pre-hospital setting.

STUDY DESIGN CROSSROADS-EEG is an investigator-initiated, prospective, multi-centre cohort study.

STUDY POPULATION Adult patients with a suspected stroke, onset of symptoms (or last seen well) \<24 hours in the pre-hospital setting.

INTERVENTION A single measurement with a dry electrode headset EEG (approximately 2 minutes recording duration) will be performed in each patient. Clinical and radiological data will be collected. EEG data will be acquired with the improved TrianecT EEG device, StrokePointer.

MAIN STUDY END POINTS

  • Proportion of patients with a technically successful EEG dataset: at least 20 seconds of usable EEG (at least 3 electrodes with good skin-electrode quality on either side, no movement artifacts, no muscle artifacts) within a measurement time of 3 minutes.
  • Diagnostic accuracy of StrokePointer for LVO stroke among patients with a suspected stroke, as measured with AUC as well as sensitivity and specificity.
03

Conditions studied

  • Ischemic Stroke
  • Stroke
  • Cardiovascular Diseases
  • Vascular Diseases
  • Central Nervous System Diseases
  • Brain Diseases
  • Nervous System Diseases
  • Cerebrovascular Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suspected acute stroke as per judgement of the ambulance personnel.
  • Age 18 years or older.
  • Onset of symptoms (or last seen well) \<24 hours.
  • Written by patient or legal representative (deferred).

Exclusion criteria

Exclusion Criteria:

- Injuries or infections of the scalp in the area of the electrode headset placement.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
275 participants (estimated)

Study arms

  • Experimental
    Dry electrode StrokePointer EEG

    All patients that are included in the study will undergo a dry electrode electroencephalography (EEG).

    Diagnostic Test: Dry electrode EEG

Interventions

  • Diagnostic testDry electrode EEG

    A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. EEG data will be acquired with Strokepointer (TrianecT B.V., Utrecht, The Netherlands). StrokePointer is a portable EEG acquisition and analysis device. The device consists of three parts: (1) StrokePointer headset with dry electrodes to measure EEG data, (2) Portable StrokePointer suitcase that contains a mobile computing device (Android phone), CE-marked (IIa) EEG amplifier and storage compartments and (3) Software to acquire, analyse and upload EEG data.

06

What researchers measure

Primary outcomes

  1. Data quality of StrokePointer

    Proportion of patients with a technically successful EEG dataset: at least 20 seconds of usable EEG (at least 3 electrodes with good skin-electrode quality on either side, no movement artifacts, no muscle artifacts) within a measurement time of 3 minutes.

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

  2. Diagnostic accuracy of StrokePointer for LVO stroke

    Diagnostic accuracy of StrokePointer for LVO stroke among patients with a suspected stroke, as measured with Area under the curve (AUC) as well as sensitivity and specificity

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

Secondary outcomes

  1. Predictive value of StrokePointer in identifying LVO stroke

    Positive and negative predictive value of StrokePointer in identifying LVO stroke

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

  2. User friendliness

    User-friendliness rating of StrokePointer by ambulance personnel and researchers: (1) after the training 80% of the users should be able to start StrokePointer and start measuring EEG-data within 120s. (2) Interviewed users score (a) usability of StrokePointer hardware on average as "makkelijk" (easy) or better, (b) StrokePointer software on average as "duidelijk" (clear) or better.

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

  3. Incidence of serious adverse device-related events (Safety of StrokePointer)

    Provided that the device is being used in line with the intended use, there are no occurrences of serious adverse device-related events in the study.

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

  4. Incidence of skin reactions (Safety of StrokePointer)

    Number of patients with an (allergic) skin reaction observed at the site of the electrode.

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

  5. Diagnostic accuracy for identifying LVO stroke subgroups

    Diagnostic accuracy for identifying LVO stroke within the following subgroups: sex (men vs. women) and age (above vs. below 60), as measured with sensitivity and specificity.

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

  6. Discriminative power of StrokePointer

    Discriminative power of StrokePointer for ischemic stroke vs stroke mimic as measured with Area under the curve (AUC) as well as sensitivity and specificity.

    Time frame: EEG-data for analysis will be recorded within 24 hours after onset of symptoms or last seen well.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 17 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 12, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06871969
Responsible party
Jonathan Coutinho (MD, PhD, neurologist, Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Mar 12, 2025
Start date
Jul 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion